Abstract
This study aimed to analyze the diagnostic value of seven autoantibodies (7-AABs) combined with carcinoembryonic antigen (CEA) and carbohydrate antigen-199 (CA199) in non-small cell lung cancer (NSCLC) and provide a new method for early screening of NSCLC. The serum levels of 7-AABs, CEA, and CA199 were determined in the NSCLC group (n = 615), benign lung disease group (n = 183), healthy control group (n = 236), and the other tumor group (n = 226). The receiver operating characteristic area under the curve (AUC) analyses were conducted to evaluate the diagnostic efficiency of 7-AABs combined with CEA and CA199 in NSCLC. The positive rate of 7-AABs detection was higher than that of a single antibody detection. The positive rate of the combination of 7-AABs in NSCLC group (27.8%) was significantly higher than that of the benign lung disease group (15.8%) and healthy control group (11.4%). The positive rate of MAGE A1 was higher in patients with squamous cell carcinoma than adenocarcinoma. The levels of CEA and CA199 in the NSCLC group were significantly higher than those of the healthy control group, but had no statistical differences compared with those of benign lung disease group. The sensitivity, specificity, and AUC of the 7-AABs were 27.8%, 86.6%, and 0.665, respectively. The combination of 7-AABs with CEA and CA199 increased the sensitivity to 34.8% and AUC to 0.689. The diagnostic efficiency was enhanced by a combination of 7-AABs, CEA, and CA199 in NSCLC, which was helpful in the screening of NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.